Vutrisiran Sodium 25 mg/mL Suppliers & Bulk Manufacturers

Available Forms: injection (prefilled syringe)

Available Strengths: 25 mg/mL

Reference Brands: Amvuttra (USA)

Category: Neurology

Vutrisiran Sodium is a Neurology product available as injection (prefilled syringe) in strengths 25 mg/mL. It corresponds to the reference brand Amvuttra (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Vutrisiran, marketed under the brand name Amvuttra, is a targeted RNA interference (RNAi) therapeutic used for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis. It is a double-stranded small interfering RNA (siRNA) designed to specifically silence the transthyretin (TTR) gene in the liver, thereby reducing the production of both mutant and wild-type TTR protein. By lowering TTR levels, vutrisiran helps prevent the accumulation of misfolded amyloid deposits that damage peripheral nerves and the heart, the primary complications of hATTR amyloidosis.

Transthyretin is a serum protein responsible for transporting vitamin A and thyroxine. Mutations in the TTR gene cause amyloid fibril formation, leading to progressive polyneuropathy, autonomic dysfunction, and cardiomyopathy. If left untreated, the disease can be fatal within 5 to 10 years. Vutrisiran is administered via subcutaneous injection once every three months, providing sustained therapeutic effects while offering a convenient dosing schedule. With its mechanism directly addressing the underlying genetic cause of hATTR amyloidosis, vutrisiran represents a significant advancement in the management of this rare, progressive, and life-threatening disease.